Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAT1 | P18440 | 7/20 | 0.67 |
| ▸ | PIM1 | P11309 | 5/20 | 0.59 |
| ▸ | MYC | P01106 | 1/20 | 0.55 |
| ▸ | MAX | P61244 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8986249 | 0.89 | PIM1 (0.65) | NAT1PIM1MYCMAXGSK3B | |
| SCHEMBL8986259 | 0.89 | PIM1 (0.65) | NAT1PIM1MYCMAXGSK3B | |
| SCHEMBL18103073 | 0.89 | PIM1 (0.65) | NAT1PIM1MYCMAXGSK3B | |
| SCHEMBL18103099 | 0.86 | NAT1 (0.63) | NAT1PIM1MYCMAXGSK3B | |
| SCHEMBL18103072 | 0.84 | NAT1 (0.79) | NAT1PIM1MYCMAXGSK3B | |
| SCHEMBL8308593 | 0.84 | NAT1 (0.65) | NAT1PIM1MYCMAXGSK3B | |
| SCHEMBL8708716 | 0.84 | NAT1 (0.65) | NAT1PIM1MYCMAXGSK3B | |
| SCHEMBL3425968 | 0.80 | NAT1 (1.00) | NAT1PIM1MYCMAXGSK3B | |
| SCHEMBL3425971 | 0.80 | NAT1 (1.00) | NAT1PIM1MYCMAXGSK3B | |
| SCHEMBL15421702 | 0.80 | NAT1 (1.00) | NAT1PIM1MYCMAXGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2019-12-10 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| WO-2016154255-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | UNIVERSITY OF MIAMI (US) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | NOTCH1, CBFB, HES1 | NAT1 867/4885PIM1 2196/4885MYC 39/4885 |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NOTCH1, CBFB, HES1 | NAT1 867/4885PIM1 2196/4885MYC 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.